centered image

centered image

Lawsuit Says Bristol-Myers Avoided $6.4 Bln Payment By Delaying Cancer Drug

Discussion in 'Hospital' started by The Good Doctor, Jun 5, 2021.

  1. The Good Doctor

    The Good Doctor Golden Member

    Aug 12, 2020
    Likes Received:
    Trophy Points:

    A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.

    According to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.


    The lawsuit said Bristol-Myers failed to use contractually required "diligent efforts" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.

    Bristol-Myers had no immediate comment.

    The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.

    —Reuters Staff


    Add Reply

Share This Page